The incentive program for senior management and key individuals implemented at the Annual General Meeting held on May 13, 2014 entitles, through the exercise of options, the holders to subscribe for new shares in the company during the second half of 2017. In total, the incentive program consists of 123,000 options which entitle the holders to one new share per option.
During the month of September, a total of 44,000 shares have been issued through the exercise of the incentive program’s options. Before the issue of new shares there were a total of 4,745,138 shares and votes in the company. As of September 30, 2017, there will be a total of 4,789,138 shares and votes in the company.
At year-end, there will be a total of 4,830,138 shares and votes in the company if the incentive program’s options are fully exercised.
For further information, please contact:
Fredrik Dalborg, CEO and President, Boule Diagnostics AB, phone +46 705-58 51 05
Fredrik Alpsten, CFO, Boule Diagnostics AB, phone + 46 706 67 31 06
About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a rapidly growing global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden and the USA. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. http://www.boule.se
This information is information that Boule Diagnostics AB is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 1 PM September 29, 2017.